The condition is better measured by looking at factors like inflammation, insulin resistance, and glucose tolerance, according to the doctor. In some cases, using BMI can result in “muscular athletes” being labeled as obese, he noted, and people with “normal” BMI can sometimes have “harmful” levels of visceral (abdominal) fat.

According to a September 2024 data brief from the Centers for Disease Control and Prevention (CDC), 40.3 percent of U.S. adults were considered obese between August 2021 and August 2023.

New guidance from a team of health experts around the world proposes expanding the definition of obesity beyond the popular body mass index (BMI) measure.

Obesity is a global public health problem, with rates steadily increasing in many regions of the world. However, the impact of this epidemic is not uniform: some countries are affected to a greater extent than others.

Childhood obesity is on the rise and is becoming an epidemic in our country and worldwide. The consequences of childhood obesity affect long-term physical, emotional, and mental health. The CDC estimates about 1 in 5 children – approximately 14.

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that from 2021 to 2023, those rates dropped from 41.9% to 40.3%.

Body Mass Index, or BMI, has long been criticized as an unreliable method for measuring obesity — and now a group of experts is sharing new recommendations for how to use it.

A group of experts from around the world are proposing an alternative way of defining clinical obesity, eschewing the commonly referenced body max index (BMI) and instead approaching the condition

BMI falls short as a way to measure obesity. Doctors need to also determine whether body fat harms a person's health.

The Lancet, a global medical journal that works with academics to identify issues in public health, hosted a Commission on Clinical Obesity on Jan. 16 in Baton Rouge to discuss a new approach to diagnosing and defining obesity.

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a half-life of up to 60 hours, and superior pharmacokinetic properties compared to other oral GLP-1 receptor agonists.

The Centers for Disease Control and Prevention (CDC) recommends walking 10,000 steps daily to maintain health and lower the risk of conditions like obesity and age-related memory loss.